OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
November 02, 2022
Learning from early market failures, the biopharma industry has worked to improve the fate of antibody drug conjugates.
June 27, 2022
ImmunoGen has formed a research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates for cancers with high unmet needs.
May 15, 2022
The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.
February 11, 2022
Piramal Pharma Solutions plans to construct a multipurpose ADC manufacturing and aseptic fill/finish facility in Grangemouth, Scotland, and to upgrades its existing API manufacturing facility in Morpeth, England.
November 02, 2021
ADC development is on a positive trajectory from a deeper understanding of therapeutic mechanisms and technological advances.
November 01, 2021
A coating technology for a staked needle prefillable syringe reduces the potential risks associated with silicone oil as a lubricant.
June 20, 2019
The company has expanded its high-potency API capability at its Riverview, MI, facility to serve the growing antibody drug conjugates market.
April 01, 2019
Drug makers continue to explore innovative ways to develop antibody-drug conjugates based on their unique potential to neutralize cancer cells.
March 01, 2019
Both empty and filled syringes must pass a range of tests to meet quality standards for biopharmaceutical drugs.
November 01, 2017
Despite the disappointing therapeutic performance of ADCs thus far, the pipeline still boasts promising prospects.